Latest Cancer Immunotherapy News

Page 2 of 2
Immutep has received encouraging feedback from the FDA on its immunotherapy eftilagimod alfa combined with KEYTRUDA for patients with low PD-L1 expression in head and neck cancer, opening potential accelerated approval pathways.
Ada Torres
Ada Torres
5 Aug 2025
Prescient Therapeutics has extended the closing date of its Share Purchase Plan to July 25, 2025, responding to shareholder demand and reinforcing strong participation. The oncology-focused biotech also highlights upcoming clinical milestones and ongoing investor engagement.
Ada Torres
Ada Torres
22 July 2025
Prescient Therapeutics has extended its Share Purchase Plan closing date to 22 July 2025, aiming to raise up to A$7 million to advance its targeted cancer therapy PTX-100 through Phase 2 clinical trials.
Ada Torres
Ada Torres
15 July 2025
Invion Limited reports no adverse events and early lesion reduction in its Phase I/II non-melanoma skin cancer trial, advancing to dose optimization.
Ada Torres
Ada Torres
29 May 2025
Immutep’s novel immunotherapy combination with radiotherapy and KEYTRUDA® has met its primary endpoint in a Phase II trial for resectable soft tissue sarcoma, showing promising early signs of improved patient outcomes.
Ada Torres
Ada Torres
26 May 2025
Immutep’s novel immunotherapy combination with KEYTRUDA and chemotherapy shows a 60.8% response rate in first-line non-small cell lung cancer, outperforming historical benchmarks especially in patients with low PD-L1 expression.
Ada Torres
Ada Torres
15 May 2025
Immutep’s combination of eftilagimod alfa (efti) and KEYTRUDA® delivers a striking 17.6-month median overall survival in head and neck cancer patients with low PD-L1 expression, a group with limited treatment options.
Ada Torres
Ada Torres
5 May 2025
Imugene’s Phase 1b trial of azer-cel, an off-the-shelf CD19 CAR T therapy, reports a 57% complete response rate in heavily pretreated diffuse large B-cell lymphoma patients, signaling a promising new option in a challenging cancer landscape.
Ada Torres
Ada Torres
14 Feb 2025
Imugene Limited reports durable patient responses in multiple cancer immunotherapy trials and strengthens its financial position with a $46 million convertible note deal and a substantial R&D tax refund.
Ada Torres
Ada Torres
31 Jan 2025
Imugene Limited has secured A$20 million through convertible notes as part of a broader A$46 million capital raise, aiming to advance its promising immuno-oncology pipeline.
Ada Torres
Ada Torres
29 Jan 2025